Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Boosted by Federated Hermes Inc.

Federated Hermes Inc. boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 205,361 shares of the pharmaceutical company’s stock after buying an additional 12,542 shares during the period. Federated Hermes Inc.’s holdings in Vertex Pharmaceuticals were worth $83,559,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sherbrooke Park Advisers LLC boosted its position in shares of Vertex Pharmaceuticals by 65.3% during the 3rd quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock valued at $920,000 after purchasing an additional 1,045 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in Vertex Pharmaceuticals by 6.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock valued at $150,550,000 after buying an additional 26,523 shares in the last quarter. Telos Capital Management Inc. lifted its stake in Vertex Pharmaceuticals by 1.6% during the fourth quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock valued at $6,133,000 after buying an additional 237 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Vertex Pharmaceuticals by 1.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock valued at $148,485,000 after buying an additional 5,514 shares in the last quarter. Finally, Machina Capital S.A.S. purchased a new stake in Vertex Pharmaceuticals during the third quarter valued at about $816,000. Institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,381 shares of company stock worth $5,203,249. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.1 %

Shares of VRTX stock opened at $393.48 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $316.43 and a 12 month high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $414.17 and its two-hundred day moving average is $396.74. The company has a market cap of $101.70 billion, a PE ratio of 28.33, a price-to-earnings-growth ratio of 1.85 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The company had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter last year, the company posted $3.33 earnings per share. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on the stock. UBS Group reduced their price objective on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Robert W. Baird lowered shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective for the company. in a research note on Wednesday, January 31st. Wells Fargo & Company increased their price target on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, Wolfe Research assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price target for the company. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.